证券代码：000989 证券简称：九芝堂 1 九芝堂股份有限公司投资者关系活动记录表 编号：20211214001 | --- | --- | --- | --- | |-------------------------|----------------------------------|----------------------------|------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | | □媒体采访 □业绩说明会 | | | | 投资者关系活动 | □新闻发布会 □路演活动 | | | | 类别 | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 国盛证券 杨春雨 | 缪牧一 | | | 时间 | 2021 年 12 月 14 日 | 10:30-12:00 | | | 地点 | 九芝堂集团第一会议室（北京） | | | | 上市公司接待人 | | | 董事会秘书韩辰骁，财务副总监、财务管控中心 ...

1 证券代码：000989 证券简称：九芝堂 九芝堂股份有限公司投资者关系活动记录表 编号：20211227003 | --- | --- | --- | |-------------------------|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 长城证券 | 医药分析师 吴欣 | | 时间 | 2021 年 12 月 | 日 18:40-19:00 | | 地点 | 电话会议 | | | 上市公司接待人 员姓名 | 董事会秘书 ...

证券代码：000989 证券简称：九芝堂 1 九芝堂股份有限公司投资者关系活动记录表 编号：20211223002 | --- | --- | --- | --- | --- | |-----------------------|--------------------------------|----------------------------------------------------------|-------|------------------------------| | | | | | | | | √特定对象调研 □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | | 动类别 | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | 参与单位名称 | 海通国际证券 | 医药分析师孟科含 | | | | 及人员姓名 | | | | | | 时间 | 2021 年 12 月 23 日 | 15:30-16:30 | | | | 地点 | 电话会议 | | | | ...

证券代码：000989 证券简称：九芝堂 1 九芝堂股份有限公司投资者关系活动记录表 编号：20220114001 | --- | --- | --- | --- | |-------------------------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000989 证券简称：九芝堂 九芝堂股份有限公司投资者关系活动记录表 编号：20220707004 | --- | --- | --- | |-------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | √现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | 2022 年 7 月 5 日 | 西部证券-吴天昊、丁健行，泰康资产-陈璟，阳光 | | 参与单位名称、 人员姓名、时间 | 保险 - 2022 年 7 月 6 日 银理财 ...

九芝堂股份有限公司 2022 年第三季度报告 证券代码：000989 证券简称：九芝堂 公告编号：2022-069 九芝堂股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是否 1 九芝堂股份有限公司 2022 年第三季度报告 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |----------------------------------------------------------|------------------|-------------------------|----------------- ...

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2022-063 九芝堂股份有限公司 关于参加湖南辖区上市公司 2022 年 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈 述或者重大遗漏负连带责任。 为进一步加强与投资者的互动交流，九芝堂股份有限公司（以下简称"公 司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公司联 合举办的 "湖南辖区上市公司 2022 年投资者网上集体接待日"活动，现将有关 事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台，采取网络远程的方式举行，投资者可以登陆"全景路演"网站 （http://rs.p5w.net）参与公司本次投资者网上集体接待日活动，活动时间为 2022 年 9 月 29 日（星期四）15:30－16:55。 届时，公司财务总监、董事会秘书、证券事务代表等相关人员将参加本次活 动，通过网络在线交流形式与投资者进行沟通。欢迎广大投资者积极参与。 特此公告。 九芝堂股份有限公司董事会 2022 年 9 月 24 日 九芝堂股份有限公司 ...

九芝堂股份有限公司 2022 年半年度报告全文 九芝堂股份有限公司 2022 年半年度报告 公告编号：2022-055 披露日期：2022 年 8 月 31 日 1 九芝堂股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人李振国、主管会计工作负责人张梁彬及会计机构负责人(会计 主管人员)毛凤云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对 投资者的实质承诺，请投资者注意投资风险。 公司已在本报告"第三节、管理层讨论与分析"中分析了公司未来发展 可能面临的风险因素和应对措施。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 九芝堂股份有限公司 2022 年半年度报告全文 目录 | --- | |------------------------------------------------------- ...

Financial Performance - The company's operating revenue for 2021 was CNY 3,784,155,236.54, representing a year-on-year increase of 6.31% compared to CNY 3,559,540,963.73 in 2020[28]. - The net profit attributable to shareholders of the listed company was CNY 270,696,505.84, a decrease of 0.59% from CNY 272,309,874.61 in the previous year[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 240,829,403.36, down 3.67% from CNY 250,004,429.28 in 2020[28]. - The net cash flow from operating activities was CNY 365,912,082.41, a significant decrease of 39.97% compared to CNY 609,555,035.41 in the previous year[28]. - The basic earnings per share for 2021 was CNY 0.3167, a decline of 2.31% from CNY 0.3242 in 2020[28]. - The diluted earnings per share also stood at CNY 0.3167, reflecting the same decrease of 2.31% compared to the previous year[28]. - Total assets increased by 3.83% to CNY 5,265,533,999.97 compared to the previous year[30]. - The company reported a total net profit of CNY 22,305,445.33 from non-recurring gains in 2021[40]. - The total revenue for the year 2021 reached ¥3,784,155,236.54, representing a year-on-year increase of 6.31% compared to ¥3,559,540,963.73 in 2020[85]. - The total revenue for the pharmaceutical industry reached ¥2,716,765,356.38, representing a year-on-year increase of 7.07%[89]. - The gross profit margin for the pharmaceutical industry was 72.90%, a decrease of 2.53% compared to the previous year[89]. Market and Product Development - The company is focusing on innovation and development in the pharmaceutical sector, aligning with national policies to enhance R&D capabilities[46]. - The company achieved sales revenue exceeding 100 million CNY for six products, including Xuexuetong injection and Liuwei Dihuang pill, with An Gong Niu Huang pill's revenue increasing by 22% year-on-year[53]. - The company has developed a series of blood-nourishing products centered around Ejiao, with the market-leading position of Donkey-hide Gelatin Blood-Nourishing Granules[53]. - The company is expanding its strategic layout in the healthcare sector, including the establishment of an internet hospital in Hunan and partnerships with Nanshan Holdings and Beijing Guangda Huichen Elderly Care Services[74]. - The company is enhancing product standards and conducting technical research on 17 products, including Liuwei Dihuang Wan and other traditional Chinese medicine products, to improve technological content and sales channels[72]. - The company is accelerating the development of innovative drugs and health products, with a focus on major, difficult, and rare diseases, while also advancing stem cell product research[140]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a target of completing at least two acquisitions in the next year[166]. Research and Development - The company has a strong focus on research and development, exploring new therapeutic effects of traditional Chinese medicine and developing new product lines[56]. - R&D investment amounted to ¥117,781,782.46 in 2021, an increase of 3.85% from ¥113,419,202.84 in 2020, representing 3.11% of operating revenue[103]. - The number of R&D personnel increased by 3.50% to 325 in 2021 from 314 in 2020, with a slight decrease in the proportion of R&D personnel to total employees from 6.90% to 6.80%[102]. - The company holds over 200 valid patents across various fields, including pharmaceuticals and health products, indicating strong R&D capabilities[62]. - The company completed 16 patent applications and received authorization for 10 patents, including 5 invention patents during the reporting period[73]. Governance and Management - The company maintains an independent operational structure, ensuring separation from the controlling shareholder in aspects such as personnel, assets, and finance[159]. - The company has established a complete procurement, production, sales, and R&D system, demonstrating its independent business capabilities[159]. - The company emphasizes investor relations, utilizing various communication methods to engage with investors and address their concerns[158]. - The company’s governance structure complies with the regulatory requirements set by the China Securities Regulatory Commission[156]. - The company’s board of directors and supervisory board operate independently, ensuring responsible governance and oversight[158]. - The company has established a comprehensive talent training program, focusing on professional and comprehensive skill development to enhance employee capabilities[196]. Strategic Initiatives - The company plans to implement a high-quality development strategy and a health ecology strategy during the 14th Five-Year Plan period[136]. - The company aims to achieve an average annual growth rate of over 8% in operating income and total profit during the 14th Five-Year Plan[135]. - The company is committed to the revitalization and development of traditional Chinese medicine, which has been elevated to a national strategy[135]. - The company is focusing on brand value enhancement and market structure optimization to counteract the risks of price reductions in pharmaceuticals[145]. - The company is prepared to adapt its business strategies in response to ongoing changes in the COVID-19 pandemic situation[148]. Financial Management - The company implemented a cash dividend policy, distributing 4.00 CNY per 10 shares, totaling 342,376,804.80 CNY in cash dividends for the reporting period[199]. - The total distributable profit for the company was 1,481,355,532.56 CNY, with cash dividends accounting for 100% of the total profit distribution[199]. - The company has not made any adjustments to its profit distribution policy during the reporting period, adhering strictly to the provisions of its articles of association[199]. - The company aims to maintain a minimum cash dividend ratio of 20% during profit distribution, considering its growth stage and significant capital expenditure plans[199].

九芝堂股份有限公司 2022 年第一季度报告全文 □ 是 √ 否 1 证券代码：000989 证券简称：九 芝 堂 公告编号：2022-016 九芝堂股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | 本报告期 | 上 ...